The Precision Peptide Company Inc. News Releases

The Precision Peptide Company Inc. Announces Extension of Investor Relations Agreement with Emerging Markets Consulting, LLC

Fri, 05 Jun 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that, further to its news release dated October 15, 2025, it has extended its existing agreement with Emerging Markets Consulting, LLC ("EMC") for the continued provision of investor relations and communication services by EMC for an additional six month term.Emerging Markets Consulting, LLCBased in Orlando, Florida, EMC brings...

The Precision Peptide Company Inc. Signs Agreement with U.S.-Based 503A Sterile Compounding Pharmacy - Peptides to be 100% Compounded in the United States

Tue, 02 Jun 2026 07:00:00 -0400

HighlightsExecuted compounding agreement with a U.S.-based 503A sterile compounding pharmacy partnerCompounding activities under the agreement expected to commence on Monday, June 1, 2026All peptides under the agreement to be 100% compounded in the United StatesDesigned to support prescription-based peptide preparation and fulfillment, including BPC-157Up to approximately 25,000 prescriptions per day in fulfillment capacity available under the agreement, with reach across all U.S....

The Precision Peptide Company to Exhibit as the Only Peptide Company at Dave Asprey's BEYOND Conference in Austin, Texas

Thu, 28 May 2026 07:30:00 -0400

HighlightsOnly peptide company exhibiting at BEYOND 2026, Dave Asprey's flagship biohacking, longevity, and consciousness conferenceThree immersive days in Austin, Texas — May 27-29, 20265,000+ attendees, 100+ speakers, 150+ exhibiting partners, and 30 experiential "hacktivations"Dedicated booth showcasing the Company's peptide product line, including the needle-free BPC-157 transdermal patchEvent comes ahead of the previously announced feature of CSO Justin Kirkland on The Human Upgrade with...

The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches

Tue, 26 May 2026 07:30:00 -0400

HighlightsOrder placed for 20,000 units of the Company's lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial releaseInitial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company websiteEach patch is formulated to deliver 2 mg of BPC-157, consistent with the 95.5% chromatographic purity and 2.02 mg measured dose per patch independently confirmed in the Company's May 19, 2026 news...

The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

Thu, 21 May 2026 07:30:00 -0400

Exclusive Agreement Gives Precision Direct Commercial Access to MMA.INC's Global Combat Sports Ecosystem, Backed by Strategic Advisors Conor McGregor and Donald Trump Jr., Cofounder John Kavanagh and Board Director Laura Sanko HighlightsExclusive access to MMA.INC's global combat sports ecosystem1 of 5M+ social media followers, 530,000 user profiles and 800+ verified gyms across 16 countriesMMA.INC's roster includes strategic advisors Conor McGregor (who was announced this week to headline UFC...

The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch

Tue, 19 May 2026 07:00:00 -0400

HighlightsThe BPC-157 patch is a wearable, needle-free product, designed to remove the injection barrier that has historically limited consumer adoption of peptide productsResults support The Precision Peptide Company Inc.'s continued progression of its lead product toward commercial launchIndependent lab results confirm 95.5% chromatographic purity and a quantified 2.02 mg dose of BPC-157 per patch¹Purity result clears the ≥95% threshold recognized across the peptide industry as the analytical...

The Precision Peptide Company's Chief Scientific Officer Justin Kirkland to Be Featured on The Human Upgrade with Dave Asprey

Thu, 14 May 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that Justin Kirkland, Co-Founder and Chief Scientific Officer of the Company's wholly-owned subsidiary Amino Innovations, will be featured as a guest on an upcoming episode of The Human Upgrade with Dave Asprey.The Human Upgrade, hosted by...

The Precision Peptide Company Inc. Announces Exclusive Strategic Marketing Partnership with Mixed Martial Arts Group Limited

Tue, 12 May 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has entered into an Exclusive Strategic Marketing Agreement (the "Strategic Marketing Agreement") dated May 8, 2026 with Mixed Martial Arts Group Limited ("MMA"), a New South Wales, Australia-based company. Under the Strategic...

The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances

Thu, 07 May 2026 07:30:00 -0400

First wearable peptide patch designed to expand BPC-157 beyond injectables and establish a multi-product transdermal peptide platform under Amino Innovations Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today provides an update on the development of its needle-free BPC-157 transdermal patch - a product...

C$1.3 Million in Proceeds Received by The Precision Peptide Company from Warrant Exercises

Tue, 05 May 2026 07:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 5, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") a publicly traded wellness company focused on advanced peptide formulations and delivery systems, announces the receipt of approximately C$1.3 million from the exercise of outstanding warrants.The proceeds strengthen the Company's balance sheet and will be used to support the continued development and expansion of its Amino Innovations platform, including...